drug_type
RELEVANT_DRUG
intervention_type
Oncolytic virus
drug_description
An oncolytic adenovirus with replication driven by the survivin (BIRC5) promoter active in high-grade glioma cells; pk7 polylysine fiber modification enables CAR-independent entry via heparan sulfate proteoglycans, producing tumor-selective oncolysis and potential anti-tumor immune activation.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Adenoviruses, Human
drug_category
ONCOLYTIC VIRUS
drug_class
Gene therapy
drug_delivery_route
Intracerebral
drug_mechanism_of_action
Engineered adenovirus that replicates selectively in survivin (BIRC5)-expressing glioma cells; pk7 polylysine fiber modification enables CAR-independent entry via heparan sulfate proteoglycans, leading to tumor-restricted viral replication, oncolysis, and secondary activation of anti-tumor immune responses.
drug_name
CRAd-S-pk7 (conditionally replicative adenovirus)
nct_id_drug_ref
NCT05139056